You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 3, 2024

CLINICAL TRIALS PROFILE FOR LETERMOVIR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Letermovir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02137772 ↗ Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) Completed Merck Sharp & Dohme Corp. Phase 3 2014-06-06 The study evaluated the efficacy and safety of letermovir (MK-8228) for the prevention of clinically-significant CMV infection in adult, CMV-seropositive recipients of allogeneic hematopoietic stem cell transplant (HSCT). The hypothesis being tested was that MK-8228 is superior to placebo in the prevention of clinically-significant CMV infection through Week 24 post-transplant.
NCT03443869 ↗ Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002) Active, not recruiting Merck Sharp & Dohme Corp. Phase 3 2018-05-03 The primary objective of this study is to evaluate the efficacy of letermovir (LET) versus valganciclovir (VGCV) in preventing CMV disease in adult kidney transplant recipients. The primary hypotheses are that LET is non-inferior to VGCV; and if non-inferiority is demonstrated, that LET is superior to VGCV, in preventing CMV disease through 52 weeks post-transplant.
NCT03728426 ↗ Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection Recruiting Merck Sharp & Dohme Corp. Phase 2 2019-01-11 The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Letermovir

Condition Name

Condition Name for Letermovir
Intervention Trials
Cytomegalovirus Infections 5
Cytomegalovirus Infection 3
Antiviral Toxicity 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Letermovir
Intervention Trials
Cytomegalovirus Infections 11
Infections 10
Communicable Diseases 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Letermovir

Trials by Country

Trials by Country for Letermovir
Location Trials
United States 46
France 13
Australia 8
Germany 8
Japan 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Letermovir
Location Trials
New York 5
California 5
Massachusetts 5
Ohio 3
North Carolina 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Letermovir

Clinical Trial Phase

Clinical Trial Phase for Letermovir
Clinical Trial Phase Trials
Phase 4 2
Phase 3 7
Phase 2 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Letermovir
Clinical Trial Phase Trials
Not yet recruiting 10
Recruiting 6
Active, not recruiting 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Letermovir

Sponsor Name

Sponsor Name for Letermovir
Sponsor Trials
Merck Sharp & Dohme Corp. 11
Assistance Publique - Hôpitaux de Paris 2
National Institute of Allergy and Infectious Diseases (NIAID) 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Letermovir
Sponsor Trials
Other 14
Industry 13
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.